| Literature DB >> 27183228 |
Olga Horakova1, Jana Hansikova1, Kristina Bardova1, Alzbeta Gardlo1,2, Martina Rombaldova1, Ondrej Kuda1, Martin Rossmeisl1, Jan Kopecky1.
Abstract
Obesity is associated with insulin resistance and impaired glucose tolerance, which represent characteristic features of the metabolic syndrome. Development of obesity is also linked to changes in fatty acid and amino acid metabolism observed in animal models of obesity as well as in humans. The aim of this study was to explore whether plasma metabolome, namely the levels of various acylcarnitines and amino acids, could serve as a biomarker of propensity to obesity and impaired glucose metabolism. Taking advantage of a high phenotypic variation in diet-induced obesity in C57BL/6J mice, 12-week-old male and female mice (n = 155) were fed a high-fat diet (lipids ~32 wt%) for a period of 10 weeks, while body weight gain (BWG) and changes in insulin sensitivity (ΔHOMA-IR) were assessed. Plasma samples were collected before (week 4) and after (week 22) high-fat feeding. Both univariate and multivariate statistical analyses were then used to examine the relationships between plasma metabolome and selected phenotypes including BWG and ΔHOMA-IR. Partial least squares-discrimination analysis was able to distinguish between animals selected either for their low or high BWG (or ΔHOMA-IR) in male but not female mice. Among the metabolites that differentiated male mice with low and high BWG, and which also belonged to the major discriminating metabolites when analyzed in plasma collected before and after high-fat feeding, were amino acids Tyr and Orn, as well as acylcarnitines C16-DC and C18:1-OH. In general, the separation of groups selected for their low or high ΔHOMA-IR was less evident and the outcomes of a corresponding multivariate analysis were much weaker than in case of BWG. Thus, our results document that plasma acylcarnitines and amino acids could serve as a gender-specific complex biomarker of propensity to obesity, however with a limited predictive value in case of the associated impairment of insulin sensitivity.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27183228 PMCID: PMC4868278 DOI: 10.1371/journal.pone.0155776
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Body weight and metabolic phenotypes of mice before and after high-fat feeding.
| Males | Females | ||||
|---|---|---|---|---|---|
| STD | HFD | STD | HFD | ||
| 14 | 82 | 11 | 73 | ||
| Week 12 | 24.7±1.4 | 25.5±1.5 | 21.6±0.9 | 22.2±1.4 | |
| Week 24 | 27.9±1.9 | 33.3±5.5 | 23.7±0.9 | 32.2±6.4 | |
| BWG | 3.2±1.0 | 7.8±4.9 | 2.2±0.9 | 10.0±5.7 | |
| Week 12 | 104±14 | 107±20 | 119±23 | 111±21 | |
| Week 22 | 111±35 | 118±26 | 95±22 | 106±23 | |
| 7±34 | 11±35 | -23±17 | -6±31 | ||
| Week 12 | 257±49 | 236±47 | 198±60 | 209±69 | |
| Week 22 | 223±81 | 274±69 | 209±63 | 277±68 | |
| Week 12 | 1304±288 | 1160±290 | 876±262 | 955±350 | |
| Week 22 | 1341±517 | 1774±420 | 1148±332 | 1433±512 | |
| 130±757 | 642±497 | 271±363 | 504±634 | ||
| Week 12 | 1.7±1.5 | 2.6±1.9 | 1.7±1.3 | 2.7±2.4 | |
| Week 22 | 4.5±4.1 | 7.9±8.2 | 3.4±2.2 | 7.7±4.5 | |
| 2.9±4.6 | 5.4±8.1 | 1.9±2.5 | 5.1±5.0 | ||
| Week 12 | 6.9±4.2 | 7.9±4.4 | 5.6±2.1 | 7.3±4.0 | |
| Week 22 | 6.9±7.0 | 9.4±7.4 | 7.8±5.9 | 9.1±5.9 | |
| Week 12 | 0.4±0.4 | 0.7±0.5 | 0.5±0.4 | 0.7±0.6 | |
| Week 22 | 1.4±1.9 | 2.5±3.3 | 0.8±0.5 | 2.1±1.5 | |
| 1.0±1.9 | 1.8±3.3 | 0.4±0.6 | 1.4±1.7 | ||
| Week 12 | 0.6±0.1 | 0.6±0.2 | 0.5±0.1 | 0.6±0.3 | |
| Week 22 | 0.5±0.2 | 0.4±0.1 | 0.5±0.2 | 0.4±0.1 | |
| Week 12 | 0.4±0.1 | 0.4±0.2 | 0.4±0.2 | 0.4±0.2 | |
| Week 22 | 0.3±0.1 | 0.4±0.1 | 0.3±0.1 | 0.4±0.1 | |
Body weight and metabolic phenotypes were assessed in male (M) and female (F) mice fed either a standard chow (STD) or high-fat (HFD) diet. High-fat feeding was initiated at 12 weeks of age, and continued for the subsequent 12 weeks (week 24); metabolic parameters were assessed at week 22, i.e. after 10 weeks of high-fat feeding. Blood glucose and plasma insulin have been measured after an overnight fast, right before the injection of glucose to assess glucose tolerance. Data are means ± SD. AUC, area under the glucose curve; BWG, body weight gain; NEFA, non-esterified fatty acids; ∆, difference between the values of a given parameter measured at week 22 and week 12; ∆Glucose and ∆Insulin, the change in blood glucose and plasma insulin levels, respectively, assessed before and 30 min after the injection of glucose in the context of glucose tolerance testing.
asignificantly different from Males STD
bsignificantly different from Females STD
csignificantly different from Females HFD.